Research Grant Application – Shared-Decision Making in MyelomaMPE, Myeloma, Patient evidence11 October 2021
Daratumumab subcutaneous, first approved treatment for newly diagnosed AL amyloidosis in EuropeAccess, AL amyloidosis23 June 2021
Impact of the COVID-19 pandemic on the healthcare and lives of myeloma or AL amyloidosis patients and their caregiversAL amyloidosis, MPE, Myeloma, Patient evidence21 June 2021
EHA 2021| Daratumumab plus lenalidomide and dexamethasone (D-Rd) shows overall survival benefit in elderly patients with transplant-ineligible newly diagnosed myelomaConferences, Myeloma14 June 2021
EHA 2021 | Daratumumab maintenance improves Progression-Free Survival (PFS) after autologous stem cell transplantation in myelomaConferences, Myeloma13 June 2021
EHA 2021 | Patient preferences in myeloma, a qualitative multinational study in myelomaConferences, Myeloma11 June 2021
Watch the webinar “COVID-19 vaccines for myeloma patients: what you need to know.”MPE, Myeloma, Videos30 April 2021
